Agentix Corp. Reports Increased Losses and Rising Expenses Amidst Financial Challenges

**Agentix Corp. (PINK: AGTX)** has recently released its quarterly report for the period ended December 31, 2024. The company is in the clinical-stage biotechnology sector, focusing on therapeutic agents for metabolic diseases. Here are the key points from their latest income statement and overall financial status:

Positive Aspects:

• Total current assets increased to $154,111, up from $106,372 in the previous quarter.
• Accumulated other comprehensive income has increased to $41,119, compared to $12,360 previously.
• Cash position improved, ending the reporting period with $8,273 compared to $6,535 at the end of the prior period.
• Professional fees decreased significantly, reducing operating expenses.

Negative Aspects:

• No revenues generated for the reporting period, maintaining a trend from the previous year.
• Net loss of $143,894 for the quarter, compared to a gain of $6,374 in the same period of 2023.
• Operating expenses totaled $96,815 compared to only $15,846 in the previous year's quarter, indicating a significant rise.
• Accumulated deficit reached $6,339,760, deteriorating from $5,954,480 earlier.
• Negative working capital of $2,916,743 raises concerns over the company's ability to meet short-term obligations.

Key Statistics:

• Net (loss) income: $(143,894)
  
• Basic and diluted loss per share: $(0.00)
  
• Operating expenses: $96,815
  
• Total assets: $154,111
  
• Total liabilities: $3,070,854
  
• Cash at end of period: $8,273
  
• Common stock outstanding: 40,066,951 shares
  

Overall, Agentix Corp. continues to face significant financial challenges, with no revenue and increasing expenses leading to substantial losses. The company is actively seeking additional funding to support ongoing operations and operational expenses. As of the date of reporting, they remain in a precarious position, heavily reliant on future financing to continue their business strategy.